• Home
  • NEW DAY MEDICINE
  • 9 (47) 2022
  • 63 — 9 (47) 2022 — Xamrayev A.A., Yuldasheva D.Kh., Shamsiyeva T.T., Haydarov D.B., DIAGNOSTIC SIGNIFICANCE OF MOLECULAR-GENETIC MARKERS IN THE DEVELOPMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE

63 — 9 (47) 2022 — Xamrayev A.A., Yuldasheva D.Kh., Shamsiyeva T.T., Haydarov D.B., DIAGNOSTIC SIGNIFICANCE OF MOLECULAR-GENETIC MARKERS IN THE DEVELOPMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE

DIAGNOSTIC SIGNIFICANCE OF MOLECULAR-GENETIC MARKERS IN THE DEVELOPMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE

Xamrayev A.A., Tashkent Medical Academy, Bukhara State Medical Institute

Yuldasheva D.Kh., Tashkent Medical Academy, Bukhara State Medical Institute

Shamsiyeva T.T., Tashkent Medical Academy, Bukhara State Medical Institute

Haydarov D.B., Tashkent Medical Academy, Bukhara State Medical Institute

Resume

In this article, 98 patients with NAFLD and 70 healthy controls were selected to study the significance of the rs641738 polymorphism of the MBOAT7 gene in the pathogenesis of NAFLD. Our studies confirmed the presence of a positive statistically significant relationship between the rs641738 polymorphism of the MBOAT7 gene and JNAYoX, and this association is especially significant in patients with developed non-alcoholic steatohepatitis.

Key words: non-alcoholic fatty liver disease, hepatic steatosis, non-alcoholic steatohepatitis, rs641738 polymorphism of the MBOAT7 gene

First page

374

Last page

381

For citation: Xamrayev A.A., Yuldasheva D.Kh., Shamsiyeva T.T., Haydarov D.B., DIAGNOSTIC SIGNIFICANCE OF MOLECULAR-GENETIC MARKERS IN THE DEVELOPMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE //New Day in Medicine 9 (47)2022 374-381 https://l.clck.bar/4ca02

LIST OF REFERENCES:

  1. Ивашкин В. Т. Диагностика и лечение неалкогольной жировой болезни печени // Методические рекомендации для врачей // Москва. – 2015. – С. 38.
  2. Ильченко А.А., Долгашева Г.М. Ожирение как фактор неалкогольной жировой болезни желчного пузыря (холецистостеатоза, стеатохолецистита) // Экспериментальная и клиническая гастроэнтерология. – 2009. – №8. – С. 80 – 93.
  3. Подымова С.Д. Современный взгляд на патогенез и проблему лечения неалкогольной жировой болезни печени // Экспериментальная и клиническая гастроэнтерология. – 2016. – №5. – С. 74 – 82.
  4. Shen H, Pollin TI, Damcott CM, McLenithan JC, Mitchell BD, Shuldiner AR. Glucokinase regulatory protein gene polymorphism affects postprandial lipemic response in a dietary intervention study. Hum Genet. 2009 Oct;126(4):567-74. doi: 10.1007/s00439-009-0700-3. Epub 2009 Jun 13. PMID: 19526250; PMCID: PMC2918876.
  5. Santoro N, Zhang CK, Zhao H, Pakstis AJ, Kim G, Kursawe R, Dykas DJ, Bale AE, Giannini C, Pierpont B, Shaw MM, Groop L, Caprio S. Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology. 2012 Mar;55(3):781-9. doi: 10.1002/hep.24806. Epub 2011 Dec 18. PMID: 22105854; PMCID: PMC3288435.
  6. Bugianesi E, Moscatiello S, Ciaravella MF, Marchesini G. Insulin resistance in nonalcoholic fatty liver disease. Curr Pharm Des. 2010;16(17):1941-1951. doi:10.2174/138161210791208875
  7. Kitade H, Chen G, Ni Y, Ota T. Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments. Nutrients. 2017 Apr 14;9(4):387. doi: 10.3390/nu9040387. PMID: 28420094; PMCID: PMC5409726.
  8. Xia Y., Huang C.X., Li G.Y., et al. Meta-analysis of the association between MBOAT7 rs641738, TM6SF2 rs58542926 and nonalcoholic fatty liver disease susceptibility. // Clin Res Hepatol Gastroenterol. 2019;43(5):533-541. doi:10.1016/j.clinre.2019.01.008
  9. Mancina R.M., Dongiovanni P., Petta S., Pingitore P., Meroni M., Rametta R., Borén J., Montalcini T., Pujia A., Wiklund O., Hindy G., Spagnuolo R., Motta B.M., Pipitone R.M., Craxì A., Fargion S., Nobili V., Käkelä P., Kärjä V., Männistö V., Pihlajamäki J., Reilly D.F., Castro-Perez J., Kozlitina J., Valenti L., Romeo S.. The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. Gastroenterology. 2016 May;150(5):1219-1230.e6. doi: 10.1053/j.gastro.2016.01.032. Epub 2016 Feb 2. PMID: 26850495; PMCID: PMC4844071.
  10. Johansen A, Rosti RO, Musaev D, Sticca E, Harripaul R, Zaki M, Çağlayan AO, Azam M, Sultan T, Froukh T, Reis A, Popp B, Ahmed I, John P, Ayub M, Ben-Omran T, Vincent JB, Gleeson JG, Abou Jamra R. Mutations in MBOAT7, Encoding Lysophosphatidylinositol Acyltransferase I, Lead to Intellectual Disability Accompanied by Epilepsy and Autistic Features. Am J Hum Genet. 2016 Oct 6;99(4):912-916. doi: 10.1016/j.ajhg.2016.07.019. Epub 2016 Sep 8. PMID: 27616480; PMCID: PMC5065650.
  11. Loomba R, Schork N, Chen CH, et al. Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study. Gastroenterology. 2015
  12. Helsley R.N., Varadharajan V, Brown A.L., et al. Obesity-Linked suppression of membrane-bound O-acyltransferase 7 (MBOAT7) drives non-alcoholic fatty liver disease. eLife 2019; 8.doi:10.7554/eLife.49882
  13. Хamrayev A.A., Yuldasheva D.H. Clinical, laboratory and molecular-genetic markers of the progression of non-alcoholic fatty liver disease (literature review and own data) // Society and innovations // Special Issue –2 (2021). – P. 399 – 406.
  14. Yuldasheva D.H., Zokirov V.Z., G`ulomova Sh.Q. Non-alcoholic fatty liver disease: Modern view of the problem // A Multidisciplinary Peer Reviewed Journal.Vol.6. Issue 12. Dec.2020. – P. 286 – 292.
  15. Yuldasheva D.H. Shadjanova N.S., Oltiboyev R.O. Non-alcoholic fatty liver disease and modern medicine // Academicia an international multidisciplinary research journal // Vol.10. Issue 11. Nov.2020. – P. 1931 – 1937.

file

download